ReCor Medical, with headquarters in Palo Alto, CA, is an innovative medical technology company focused on transforming the management of hypertension, the leading cardiovascular risk factor in the world. ReCor has pioneered the innovative, minimally invasive use of ultrasound in renal denervation to lower blood pressure in patients with hypertension. The company is focused on investing in high quality product development efforts, as well as rigorous clinical studies to create a strong foundation for future clinical adoption.

ReCor Medical is a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd. Otsuka Medical Devices focuses on the global development and commercialization of endovascular therapies that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical treatment. Otsuka Medical Devices Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd., a leading global health care group listed on the Tokyo Stock Exchange (JP 4578). With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of app. US$13 billion in the fiscal year ended December 2019 and has a market capitalization of app. US$25 billion.  http://www.omd.otsuka.com/en | http://www.otsuka.com/en/

The ReCor Global Clinical Trial Program 

The ReCor Global Clinical Trial Program for Hypertension consists of four independently powered, blinded, randomized, sham-controlled studies evaluating more than 600 subjects with essential and resistant hypertension.  

These studies, with additional supportive evidence from the ACHIEVE, RADIOSOUND and other clinical studies in-planning (including a Global Registry), will help provide a broad body of safety and efficacy outcome data for the potential future integration of the Paradise System as a treatment option for uncontrolled hypertension.